AnaptysBio, Inc.ANABNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +378.77% | +286.84% | +102.93% | +154.26% | +151.08% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +41166.60% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +14.53% | +14.34% | +5.32% | +0.86% | -8.73% |
| Weighted Average Shares Diluted Growth | +14.53% | +14.34% | +5.32% | +0.43% | +2.94% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +495.02% | +152.28% | +137.79% | +520.62% | -16.96% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +6.95% | +4.00% | -21.56% | -28.44% | -24.69% |
| Book Value per Share Growth | -29.76% | -37.72% | +0.00% | +0.00% | -42.47% |
| Debt Growth | -9.98% | -95.25% | -10.92% | +2000.46% | +1712.31% |
| R&D Expense Growth | +4.22% | +11.17% | -9.94% | -25.60% | -39.99% |
| SG&A Expenses Growth | -0.80% | +14.52% | +14.14% | -3.34% | +54.89% |